| Followers | 425 |
| Posts | 20207 |
| Boards Moderated | 1 |
| Alias Born | 02/22/2010 |
Wednesday, April 19, 2017 10:40:25 PM
$MBRX .86 now... have accumulated shares (good size) .865 avg and looking to add ass see fit as down from IPO 9 level
. Moleculin recently received Orphan Drug designation for Annamycin to treat acute myeloid leukemia
https://www.owler.com/reports/moleculin/brief-moleculin-receives-orphan-drug-designation-f/1490211841470?utm_source=twitter&utm_medium=social&utm_campaign=sectorNews_Pharmaceuticals
. Moleculin Biotech Just Appointed Theradex Systems as CRO to Manage Phase I/II Annamycin Trial http://finance.yahoo.com/news/moleculin-biotech-appoints-theradex-systems-113000182.html
Moleculin Biotech, Inc., (MBRX) is focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center
Development Pipeline http://www.moleculin.com/development-pipeline/#.WPggCjgxLEc.twitter
. Moleculin recently received Orphan Drug designation for Annamycin to treat acute myeloid leukemia
https://www.owler.com/reports/moleculin/brief-moleculin-receives-orphan-drug-designation-f/1490211841470?utm_source=twitter&utm_medium=social&utm_campaign=sectorNews_Pharmaceuticals
. Moleculin Biotech Just Appointed Theradex Systems as CRO to Manage Phase I/II Annamycin Trial http://finance.yahoo.com/news/moleculin-biotech-appoints-theradex-systems-113000182.html
Moleculin Biotech, Inc., (MBRX) is focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center
Development Pipeline http://www.moleculin.com/development-pipeline/#.WPggCjgxLEc.twitter
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
